⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19189815 | 0.93 | LMNA (0.43) | — | |
| SCHEMBL27383505 | 0.91 | TSHR (0.44) | — | |
| SCHEMBL25976942 | 0.91 | TSHR (0.44) | — | |
| SCHEMBL28133296 | 0.91 | TSHR (0.44) | — | |
| SCHEMBL24216138 | 0.91 | TSHR (0.44) | — | |
| SCHEMBL82068 | 0.85 | — | — | |
| SCHEMBL23735528 | 0.81 | EPHX2 (0.53) | — | |
| SCHEMBL6339160 | 0.79 | — | — | |
| SCHEMBL21137557 | 0.79 | LMNA (0.43) | — | |
| SCHEMBL21137591 | 0.79 | LMNA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | claimed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | claimed |
| US-9408926-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE S.A. (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20140161732-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | BRACCO SUISSE S.A. (CH) | 2014-06-12 | — | — | US | disclosed |
| US-20130266519-A1 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES | BRACCO INTERNATIONAL B.V. (NL) | 2013-10-10 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| WO-2007003536-A1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| US-20050130910-A1 | Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-16 | — | — | US | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |